Formulation and food effects on the oral absorption of a poorly water soluble, highly permeable antiretroviral agent.
DPC 961 is a low-solubility, high-permeability, second-generation non-nucleoside reverse transcriptase inhibitor. The purpose of these studies was to evaluate the effects of drug substance and formulation variables on DPC 961 oral absorption, and to compare fed and fasted state oral absorption. To accomplish this, groups of four to six dogs were dosed with various formulations of DPC 961 under fasted or fed conditions, and DPC 961 pharmacokinetics were examined. Absolute oral bioavailability, based on i.v. AUC in the same dogs, was 24% after a suspension dose in fasted dogs and was 51% in fed dogs. Bioavailability with an unoptimized tablet formulation was 30% in fasted dogs and 86% in fed dogs. DPC 961 oral absorption was shown to be dependent on drug substance particle size in fasted dogs, after dosing with a tablet formulation where only the drug substance particle size was varied, but there was no difference in fed dogs. AUC and C(max) increased in proportion with increases in tablet strength from 100 to 400 mg, using tablets manufactured from a common granulation. Tablets made with 50 and 66% drug loadings showed similar relative oral bioavailabilities. Tablets prepared with two different polymorphic forms of DPC 961 were also compared, and these were found to be equivalent. These studies provided a useful component of the formulation development process, to help identify and control the variables affecting oral absorption of this potential new therapeutic agent.
DuPont Pharmaceuticals Company, P.O. Box 80400, Wilmington, Delaware 19880-0400, USA. aungst@absorption.com
Bruce J
BJ
Aungst
Nhung H
NH
Nguyen
Nancy J
NJ
Taylor
Dilbir S
DS
Bindra
D000284:Administration, Oral; D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology*; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D004285:Dogs; D005260:Female; D018565:Food-Drug Interactions; D023421:Models, Animal; D010316:Particle Size; D011799:Quinazolines / Q000097:blood / Q000493:pharmacokinetics*; D052999:Quinazolinones; D012995:Solubility; D013607:Tablets / Q000737:chemistry; D014867:Water / Q000737:chemistry
D019380:Anti-HIV Agents; C413505:DPC 961; D011799:Quinazolines; D052999:Quinazolinones; D013607:Tablets; D014867:Water